Quest Diagnostics' Oncology segment provides a comprehensive suite of diagnostic solutions for cancer detection, diagnosis, and monitoring. This includes advanced genomic testing, such as next-generation sequencing (NGS) for comprehensive genomic profiling, and liquid biopsy tests for monitoring treatment response and detecting minimal residual disease. Research and development efforts focus on developing new biomarkers and assays for early cancer detection and personalized treatment strategies. Technologies used include PCR, immunohistochemistry, and advanced molecular techniques. The segment addresses a wide range of cancers, impacting patient outcomes by enabling earlier and more accurate diagnoses, guiding treatment decisions, and monitoring disease progression. Quest Diagnostics collaborates with pharmaceutical companies and research institutions to advance cancer diagnostics and improve patient care. Future opportunities include expanding the test menu, developing companion diagnostics, and leveraging AI/ML for improved data analysis and interpretation.

The Neurology segment at Quest Diagnostics focuses on providing diagnostic services for neurological disorders. This includes tests for diagnosing and monitoring conditions such as multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Research and development activities are centered on developing new biomarkers and assays for early detection and monitoring of neurological diseases. Technologies used include advanced imaging techniques, genetic testing, and cerebrospinal fluid analysis. The segment aims to improve patient outcomes by enabling earlier and more accurate diagnoses, guiding treatment decisions, and monitoring disease progression. Quest Diagnostics collaborates with pharmaceutical companies and research institutions to advance neurological diagnostics and improve patient care. Future opportunities include expanding the test menu, developing companion diagnostics, and leveraging AI/ML for improved data analysis and interpretation.

Quest Diagnostics' Cardiometabolic segment offers a wide array of diagnostic tests and services related to cardiovascular and metabolic health. This includes tests for assessing cholesterol levels, blood glucose, and other biomarkers associated with heart disease and diabetes. Research and development efforts focus on developing new biomarkers and assays for early detection and risk assessment of cardiovascular and metabolic diseases. Technologies used include immunoassay, mass spectrometry, and genetic testing. The segment aims to improve patient outcomes by enabling early detection of risk factors, guiding treatment decisions, and monitoring disease progression. Quest Diagnostics collaborates with pharmaceutical companies and research institutions to advance cardiometabolic diagnostics and improve patient care. Future opportunities include expanding the test menu, developing companion diagnostics, and leveraging AI/ML for improved data analysis and interpretation.